MPLT
MapLight Therapeutics, Inc.Company Information
- Company Name
- MapLight Therapeutics, Inc.
- CIK
- CIK0001770069
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- MPLT: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- MPLT
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-14
- Last sale
- 2026-09-16
- Shares purchased (TTM)
- 11,833,781
- Shares sold (TTM)
- 459,191
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 22,137,375
- Shares outstanding
- 45,431,359
- Ownership
- 48.73%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 18.91%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||
| Cash And Cash Equivalents At Carrying Value | 72 | 56 | 47 | 64 | ||||||
| Short Term Investments | 233 | 254 | 258 | 163 | ||||||
| Prepaid Expense And Other Assets Current | 14 | 17 | 20 | 18 | ||||||
| Assets Current | 319 | 327 | 325 | 245 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | ||||||
| Long Term Investments | 47 | 85 | 148 | - | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 2 | 5 | 5 | 6 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 5 | ||||||
| Assets | 368 | 419 | 480 | 257 | ||||||
Liabilities Current | ||||||||||
| Accounts Payable Current | 2 | 3 | 3 | 2 | ||||||
| Accrued Liabilities Current | 16 | 10 | 12 | 14 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 19 | 14 | 16 | 19 | ||||||
| Deferred Revenue Current | - | 0 | 0 | 1 | ||||||
| Operating Lease Liability Noncurrent | 1 | 5 | 5 | 5 | ||||||
| Liabilities Noncurrent | - | - | - | 5 | ||||||
| Liabilities | 20 | 19 | 21 | 24 | ||||||
Temporary Equity | ||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 831 | 822 | 819 | 7 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | -0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -481 | -421 | -361 | -281 | ||||||
| Stockholders Equity | 348 | 400 | 458 | -274 | ||||||
| Liabilities And Stockholders Equity | 368 | 419 | 480 | 257 | ||||||
| Series D Redeemable Convertible Preferred Stock | - | - | 0 | 0 | ||||||
| Series C Redeemable Convertible Preferred Stock | - | - | 0 | 0 | ||||||
| Series B1 Redeemable Convertible Preferred Stock | - | - | 0 | 0 | ||||||
| Series B Redeemable Convertible Preferred Stock | - | - | 0 | 0 | ||||||
| Series A1 Redeemable Convertible Preferred Stock | - | - | 0 | 0 | ||||||
| Series A Redeemable Convertible Preferred Stock | - | - | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 1,465 | ||||||
| Common Stock Shares Issued | 45 | 45 | 44 | 1 | ||||||
| Shares Outstanding | 45 | 45 | 44 | 1 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMapLight Therapeutics, Inc. (MPLT) — SEC Financial Statements & Analysis
MapLight Therapeutics, Inc. (MPLT) is a pharmaceutical preparations company, incorporated in DE. MapLight Therapeutics, Inc. trades on Nasdaq as: MPLT. MapLight Therapeutics, Inc. (MPLT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, MapLight Therapeutics, Inc. carries a market cap of $1.63B, a P/E ratio of -5.77x, a P/B ratio of 4.67x, an enterprise value of $1.56B, and an EV/EBITDA multiple of -5.25x. On profitability, it posts a Return on Equity (ROE) of -80.97%, a Return on Assets (ROA) of -76.56%, and a Return on Invested Capital (ROIC) of -107.40%. Per share, it reports EPS of $-6.21, diluted EPS of $-6.21, free cash flow per share of $-5.17, and a dividend per share of $0.00. On the balance sheet, it maintains a current ratio of 16.52x, a quick ratio of 15.79x, working capital of $299.49M, a debt-to-equity ratio of 0.06x, a debt ratio of 0.05, free cash flow of $-234.70M (TTM), and net debt of $-71.63M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.63B
- P/E TTM
- -5.77x
- EPS TTM
- $-6.21
- P/B TTM
- 4.67x
- ROE TTM
- -80.97%
- ROA TTM
- -76.56%
- Debt To Equity
- 0.06x
- Free Cash Flow TTM
- $-234.70M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is MapLight Therapeutics, Inc. in?
MapLight Therapeutics, Inc. (MPLT) operates in the Pharmaceutical Preparations industry.
What exchange does MPLT trade on?
MapLight Therapeutics, Inc. (MPLT) trades on the Nasdaq.
Where is MapLight Therapeutics, Inc. incorporated?
MapLight Therapeutics, Inc. is incorporated in DE.
When was MapLight Therapeutics, Inc. (MPLT)'s most recent SEC filing?
MapLight Therapeutics, Inc. (MPLT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is MPLT's market cap?
MapLight Therapeutics, Inc. (MPLT) has a market capitalization of $1.63B as of 2026-06-30.
What is MPLT's EPS (earnings per share)?
MapLight Therapeutics, Inc. (MPLT)'s trailing twelve month EPS is $-6.21 as of 2026-06-30.
What is MPLT's ROE (return on equity)?
MapLight Therapeutics, Inc. (MPLT)'s trailing twelve month Return on Equity (ROE) is -80.97% as of 2026-06-30.
What is MPLT's ROA (return on assets)?
MapLight Therapeutics, Inc. (MPLT)'s trailing twelve month Return on Assets (ROA) is -76.56% as of 2026-06-30.
What is MPLT's ROIC (return on invested capital)?
MapLight Therapeutics, Inc. (MPLT)'s trailing twelve month Return on Invested Capital (ROIC) is -107.40% as of 2026-06-30.
What is MPLT's EV/EBITDA?
MapLight Therapeutics, Inc. (MPLT)'s trailing twelve month EV/EBITDA is -5.25x as of 2026-06-30.